ArticleInternational journal of clinical and experimental pathology2015

Hypomethylation of DNA-binding inhibitor 4 serves as a potential biomarker in distinguishing acquired tamoxifen-refractory breast cancer.

Yonghui Zhang et al.PubMed ↗Full text ↗

No numbers read from the abstract.